Next week, drugmakers will arrive at the JPMorgan Healthcare Conference in San Francisco feeling far more confident than in ...

World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...

Alliance brings together complementary strengths in commercialization strategy, cross-functional launch readiness, ...

The gene therapy success with Baby KJ, along with a new FDA program, have companies more interested in treating rare disease.

Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest ...

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...

Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced ...

Dr. Makary’s right-hand man at the FDA, Dr. Vinay Prasad, has long expressed similar thoughts, writing: ...

Johnson & Johnson said on Thursday that it has reached an agreement with U.S. President Donald Trump's administration to cut ...

Meanwhile, another $70 million to $80 million of IPO proceeds is expected to fund the launch a phase 1b study of its second ...